Oncotelic Therapeutics to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
Oncotelic Therapeutics will present its proprietary PDAOAI platform at Qdrant Vector Space Day 2026, highlighting how it accelerated two drug candidates from concept to investigational new drug filings in under two years, significantly reducing time and cost.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI(TM) drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026, scheduled for June 11 in San Francisco. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years. This represents a significant reduction in the time and cost traditionally associated with pharmaceutical development, highlighting the potential for AI to transform oncology drug discovery.
The presentation will detail several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations. Additionally, the platform has indexed approximately 28 million PubMed biomedical abstracts on Qdrant Cloud, enabling advanced vector search technologies to support large-scale biomedical research. Oncotelic said the platform leverages these capabilities to accelerate oncology drug discovery efforts, addressing critical unmet needs in cancer treatment.
The implications of this announcement are substantial for the pharmaceutical industry. Traditional drug development often takes a decade or more and costs billions of dollars. Oncotelic's ability to advance two candidates to investigational new drug filings in under two years suggests that AI-driven platforms could dramatically compress development timelines, potentially bringing life-saving therapies to patients faster and at lower cost. This could also enable smaller biotech firms to compete more effectively with large pharmaceutical companies by reducing the capital required for early-stage research.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products aimed at high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, contributing to a robust portfolio of inventions. Beyond its internal pipeline, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
For more information, the full press release is available at https://ibn.fm/Ce72F. The latest news and updates relating to OTLC can be found in the company’s newsroom at https://ibn.fm/OTLC.